Japanese Research Institute to Distribute GeneBio’s Proteomics Software
GeneBio has signed a distribution deal for its mass spec protein-identification software with the Bioinformatics Institute for Global Good in Japan, the company said this week.
Tokyo-based BiGG will start “an extensive distribution campaign” for GeneBio’s Phenyx software in Japan, using its business relationships with Hitachi Software Engineering and Netwell, according to Geneva-based GeneBio.
BiGG, founded in 2002, focuses on protein research programs and has links both to academic institutions and commercial organizations. The agreement paves the way for the distribution of other GeneBio products in Japan through BiGG an its member companies, according to GeneBio.
GeneBio’s Phenyx software was developed in collaboration with the Swiss Institute of Bioinformatics and includes a scoring system developed at GeneProt in Geneva. It allows users to identify and characterize proteins and peptides from mass-spectrometry data.
DOE Awards PNNL, ORNL $2M for Biological Computing Research
The US Department of Energy’s Office of Advanced Scientific Computing Research has awarded Pacific Northwest National Laboratory and Oak Ridge National Laboratory $1 million each to develop high-performance computing technology to suppport proteomics, biomolecular simulations, and biological network analysis.
The so-called BioPilot project will develop software and computer infrastructures “that will address the areas of biology determined to have the greatest need for data-intensive computing,” according to a statement from PNNL.
Earlier this year, DOE selected ORNL’s Center for Computational Sciences to lead a partnership with a goal of building a supercomputer with a peak capacity of more than 250 teraflops by 2007.
Dyax Acquires Second HTS Flexchip Instrument
HTS Biosystems will provide a Flexchip kinetic analysis instrument to Dyax, the firm said this week.
According to HTS, this is the second Flexchip instrument to be sold to Dyax. The Flexichip combines the data quality of surface plasmon resonance with the throughput of chip array technology to deliver comparative, quantitative affinity and kinetic ranking of antibodies or other biomiolecules in a label-free, parallel format.
HTS said that it will work with Dyax to provide information about the instrument at technical conferences.
Bruker and Albany NanoTech Pen X-ray Analysis Collaboration
Bruker AXS will provide Albany NanoTech its D8 DISCOVER for Wafers technology, the company said this week.
The tool enables researchers to determine the structural characterization of nanolayers from 0.1 to 1000 nm, Bruker said in a statement.
Albany NanoTech will use the platform to analyze semiconductor heterostructures, and to develop new kinds of nanomaterials.
Financial terms of the agreement were not disclosed.
Inpharmatica Licenses Biopendium Database to Fifth Japanese Customer
Inpharmatica has sold an online subscription to its Biopendium protein-annotation database to Shionogi of Japan, the company said this week.
The subscription, the fifth to a Japanese customer, was sold through PharmaDesign, Inpharmatica’s sales and marketing partner in Japan.
Biopendium, the protein annotation component of Inpharmatica’s PharmaCarta platform, provides sequence annotation for over 150 organisms. The company recently added a microarray analysis module.
Kalypsys to Equip LANL with Protein Expression, Purification Tech
Kalypsys has agreed to provide Los Alamos National Laboratory with its automated, high-throughput protein expression and purification technologies.
Los Alamos plans to use the technology to “gain a deeper understanding of the different processes in which bacteria are involved to address the challenges of climate stabilization, clean energy production, and bioremediation,” Andrew Bradbury of the Los Alamos bioscience division said in a statement.
Financial terms of the deal were not disclosed.
As Expected, Ciphergen Sells Chromatography Business to Pall for $32M
Ciphergen has sold its BioSepra process-chromatography business to Pall for roughly $32 million. See ProteoMonitor, Nov. 5, for more information about the sale.